Variable | HR represents | HR (95%CI) | P value |
---|---|---|---|
Total population | |||
Age | Per 1-year increment | 1.018 (0.999–1.038) | 0.066 |
Male | Versus female | 2.418 (1.445–4.046) | 0.001 |
Duration of AF | < 0.001 | ||
Persistent | Versus paroxysmal | 0.781 (0.352–1.737) | 0.545 |
Permanent | Versus paroxysmal | 2.379 (1.156–4.896) | 0.019 |
Warfarin | Yes versus no | 1.200 (0.661–2.179) | 0.548 |
TiTR | ≥ 66% versus < 66% | 0.571 (0.137–1.656) | 0.243 |
eGFR | Per 1 ml/(min·1.73 m2) increment | 0.984 (0.972–0.995) | 0.006 |
Individuals with EHRA Type 1 VHDs | |||
Age | Per 1-year increment | 1.044 (0.997–1.092) | 0.067 |
Male | Versus female | 1.817 (0.687–4.808) | 0.229 |
Duration of AF | 0.277 | ||
Persistent | Versus paroxysmal | 1.994 (0.196–20.257) | 0.560 |
Permanent | Versus paroxysmal | 3.937 (0.496–31.278) | 0.195 |
TiTR | ≥ 66% versus < 66% | 0.491 (0.124–1.945) | 0.311 |
Warfarin | Yes versus no | 0.949 (0.334–2.700) | 0.922 |
eGFR | Per 1 ml/(min·1.73 m2) increment | 0.988 (0.967–1.010) | 0.281 |
Individuals with EHRA Type 2 VHDs | |||
Age | Per 1-year increment | 1.003 (0.976–1.093) | 0.269 |
Male | Versus female | 1.439 (0.323–6.413) | 0.633 |
Duration of AF | 0.145 | ||
Persistent | Versus paroxysmal | 33.672 (1.001–1132.496) | 0.050 |
Permanent | Versus paroxysmal | 7.210 (0.544–95.538) | 0.134 |
CHA2DS2-VASc score | Per 1 score increment | 0.482 (0.214–1.089) | 0.079 |
Warfarin | Yes versus no | 1.122 (0.196–6.422) | 0.897 |
eGFR | Per 1 ml/(min·1.73 m2) increment | 1.000 (0.965–1.037) | 0.985 |
Individuals without VHDs | |||
Age | Per 1-year increment | 0.991 (0.961–1.022) | 0.568 |
Male | Versus female | 3.936 (1.780–8.706) | 0.001 |
Duration of AF | 0.003 | ||
Persistent | Versus paroxysmal | 0.561 (0.223–1.412) | 0.220 |
Permanent | Versus paroxysmal | 1.866 (0.769–4.528) | 0.168 |
CHA2DS2-VASc score | Per 1 score increment | 1.136 (0.927–1.392) | 0.217 |
Warfarin | Yes versus no | 1.270 (0.528–3.053) | 0.594 |
eGFR | Per 1 ml/(min·1.73 m2) increment | 0.975 (0.959–0.992) | 0.003 |